Clinical Trials Browser

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06120140 2026-03-13

COCOON

Phase 2 Recruiting

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02974647 2026-02-27

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Phase 2 Recruiting

83 enrolled

Lymphoid

Lymphoma, Recurrence

NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Phase 2 Recruiting

50 enrolled

Myeloid

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT07359859 2026-02-17

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Phase 2 Recruiting

40 enrolled

Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

NCT05592015 2026-02-10

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Phase 2 Recruiting

30 enrolled

Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT07356245 2026-01-21

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Phase 2 Recruiting

44 enrolled

DermatologicLymphoidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04644211 2026-01-08